<DOC>
	<DOCNO>NCT02694328</DOCNO>
	<brief_summary>This study evaluate weight gain ALKS 3831 compare olanzapine adult subject schizophrenia .</brief_summary>
	<brief_title>A Study ALKS 3831 Adults With Schizophrenia ( The ENLIGHTEN-2 Study )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Subject body mass index ( BMI ) 18.030.0 kg/m^2 , inclusive , Visit 1 Visit 2 Subject meet DSM5 criterion primary diagnosis schizophrenia Subject appropriate outpatient treatment ; hospitalization acute exacerbation schizophrenia within 6 month Visit 1 Subject maintain stable body weight ( change &lt; /= 5 % ) least 3 month prior Visit 1 base selfreport Additional criterion may apply Subject follow psychiatric condition per DSM5 criterion : Diagnosis schizoaffective disorder bipolar I II disorder , current , untreated unstable major depressive disorder Clinically significant cognitive difficulty present within past 2 year could interfere participation study Druginduced toxic psychosis Any psychiatric condition could interfere participation study Subject pose current suicide risk Visit 1 Visit 2 opinion investigator Subject inflammatory bowel disease gastrointestinal disorder associate weight loss , anorexia nervosa , binge eat disorder Additional criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Alkermes</keyword>
	<keyword>ALKS 3831</keyword>
	<keyword>Samidorphan</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Olanzapine</keyword>
	<keyword>Weight</keyword>
</DOC>